The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|20|3636-3643

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.20, 2013-10, pp. : 3636-3643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy

By  

Urologia Internationalis, Vol. 93, Iss. 1, 2013-11 ,pp. : 49-54

Karger

Access to resources Recommend Favorite

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report

By  

Case Reports in Oncology, Vol. 5, Iss. 2, 2012-06 ,pp. : 320-324

Karger

Access to resources Recommend Favorite

Castrate-resistant prostate cancer: the right targets and combinations

By Karakunnel Joyson   Dahut William  

Therapy, Vol. 5, Iss. 1, 2008-01 ,pp. : 57-61

Future Medicine

Access to resources Recommend Favorite

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 250-256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer

By  

Reviews on Recent Clinical Trials, Vol. 11, Iss. 4, 2016-10 ,pp. : 317-323

Bentham Science Publishers

Access to resources Recommend Favorite